Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.
about
Vaccinology in the third millennium: scientific and social challengesHLA-DPB1 and HLA class I confer risk of and protection from narcolepsyIncidence of Narcolepsy in GermanyA coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.Pandemic influenza vaccine & narcolepsy: simulations on the potential impact of bias.Mechanistic insights into influenza vaccine-associated narcolepsy.Using the social structure of markets as a framework for analyzing vaccination debates: The case of emergency polio vaccination.Challenges in the development of therapeutics for narcolepsy.Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™.[Narcolepsy with cataplexy: an autoimmune disease?].Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.Spontaneous reporting of suspected narcolepsy after vaccination against pandemic influenza A (H1N1) in Germany.Absence of anti-hypocretin receptor 2 autoantibodies in post pandemrix narcolepsy cases.Autoimmunity in narcolepsy.Narcolepsy in Saudi patients before and after the 2009 H1N1 vaccination. The experience of 2 referral centers.Evaluating interest in an influenza A(H5N1) vaccine among laboratory workers who work with highly-pathogenic avian influenza viruses in the United States.AS03- and MF59-Adjuvanted Influenza Vaccines in Children.
P2860
Q24261399-EC25406B-2F3D-445D-987F-275888383CE3Q30370632-F2A6ED68-38A6-4F6B-92FA-B6739BA24ADEQ30374045-7EE21569-C699-4CC7-819A-2AF22ABD0F2EQ30376157-51B7DA8F-0892-4EC9-9AE8-895FB51CD6F2Q30376254-84762D7B-DF75-4A91-B1C1-8250477FF9A2Q30385564-37A71A6A-D7B5-4C47-8177-2214E7BFDA7EQ30386292-8447620F-5AFC-4BF4-BFC4-43BFCDC4D66BQ37135403-909BC70C-335A-466F-B8FE-09AC04BDBA22Q38684472-CAD19A3B-C17E-4BFA-93DE-237E590FEE16Q38804897-7ECFF7F5-E639-4873-9EEC-4CA29848F276Q41118592-00AE620A-F0E6-4E3F-B1A3-3E1666587A18Q41583882-04BAF1E9-A845-4382-9AA3-3C68937779B6Q41995022-D5EE6109-6B4C-4F90-A26D-7F3D89857CA5Q42005677-4CFCB35C-EF33-4F1A-AA5F-655E8A18D7E6Q46128712-F99C0813-B399-45D9-9FD3-1E1DCE96A21FQ46172090-EE89FCFC-AF25-4004-8E02-A85915B8D48BQ47361556-A970C5D5-5B54-4620-856F-2C7D514FC83FQ47377692-835E77B0-9793-4263-913D-42011CA2AFA1Q47658890-FDD55898-CC6F-4BA4-93AA-D98F5F9271BA
P2860
Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Risk of narcolepsy associated ...... c influenza vaccine in Quebec.
@ast
Risk of narcolepsy associated ...... c influenza vaccine in Quebec.
@en
type
label
Risk of narcolepsy associated ...... c influenza vaccine in Quebec.
@ast
Risk of narcolepsy associated ...... c influenza vaccine in Quebec.
@en
prefLabel
Risk of narcolepsy associated ...... c influenza vaccine in Quebec.
@ast
Risk of narcolepsy associated ...... c influenza vaccine in Quebec.
@en
P2093
P2860
P50
P1433
P1476
Risk of narcolepsy associated ...... c influenza vaccine in Quebec.
@en
P2093
Dominique Petit
Geneviève Deceuninck
Manale Ouakki
Marie-Josée Quinn
Philippe De Wals
P2860
P304
P356
10.1371/JOURNAL.PONE.0108489
P407
P577
2014-09-29T00:00:00Z